BioSpace News Archive

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced a successful end-of-Phase 2 Meeting with the U.S. Food & Drug Administration (FDA), supporting the advancement of pegozafermin into Phase 3 in NASH.

Aurora Spine Corporation today announced the publication of the first 6-month clinical evaluation of its ZIP™ fusion implant in the Journal of Pain Research.

OKYO Pharma Limited is pleased to announce the last patient of a planned 240-patient double-blind placebo-controlled phase 2 clinical trial of OK-101 to treat DED has completed the 12-week OK-101 dosing study.

Nanoscope Therapeutics today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately.

Atsena Therapeutics today announced positive 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

Acino today announced that it has completed the acquisition of M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

IntelGenx Technologies Corp. announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “ Board ”) effective December 2, 2023.

Cogent Biosciences, Inc. today announced the details of its investor webcast being held Monday, December 11, 2023 at 8:00 a.m. ET (5:00 a.m. PT).

Sagimet Biosciences Inc. today announced its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual fireside chat at 12:00 p.m. ET / 9:00 a.m. PT on Wednesday, December 6, 2023.